rs1837253 — TSLP Upstream Variant

TSLP: The Allergy Master Switch — and the Variant That Turns It Down

Thymic stromal lymphopoietin (TSLP)¹¹ Thymic stromal lymphopoietin (TSLP)
An epithelial-derived cytokine that acts as the master regulator of allergic immune responses is one of the most important proteins in immunology that most people have never heard of. Made by cells lining the skin, airways, and gut in response to injury or microbial signals, TSLP sits at the very top of the allergic inflammation cascade. When epithelial cells sense damage or infection, they release TSLP, which then activates dendritic cells and polarises them toward a Th2 immune profile²² Th2 immune profile
The "type 2" arm of the immune system, which drives allergic responses, asthma, and eczema rather than defense against bacteria or viruses. TSLP is, in essence, the molecular switch that flips the immune system from tolerance to allergy.

The rs1837253 variant sits 5.7 kilobases upstream of the TSLP transcription start site on chromosome 5q22.1. The common C allele allows robust TSLP expression when the airways or skin are stimulated. The protective T allele — present in roughly 26% of Europeans but up to 62% of East Asians — reduces how strongly the gene responds to inflammatory signals. This is not simply a subtle statistical association: direct measurement of TSLP protein in nasal epithelial cells³³ direct measurement of TSLP protein in nasal epithelial cells shows that people with one T allele (CT) secrete 1.8-fold less TSLP after stimulation, while those with two T alleles (TT) secrete 2.5-fold less TSLP than CC homozygotes. Lower TSLP means fewer dendritic cells primed for Th2 responses, fewer mast cells activated, and a less reactive allergic baseline throughout the airways.

The Mechanism

The T allele at rs1837253 alters regulatory elements in the TSLP upstream region that control transcriptional activity — particularly the inducibility of the longer isoform of TSLP. Studies of TSLP isoforms⁴⁴ Studies of TSLP isoforms show that the long-form TSLP is more potent in driving Th2 polarisation and is produced predominantly in response to pro-inflammatory stimuli like double-stranded RNA (from viruses) and bacterial signals. The T allele reduces how strongly these stimuli can upregulate long-form TSLP, effectively dampening the epithelial alarm signal.

Crucially, rs1837253 does not appear to be in strong linkage disequilibrium with other nearby TSLP variants (unlike some other loci in the gene). This independent segregation pattern suggests rs1837253 is itself a functionally important variant rather than merely a proxy for another causal site. Downstream, lower TSLP translates directly to less OX40L upregulation on dendritic cells⁵⁵ OX40L upregulation on dendritic cells
OX40L is a co-stimulatory molecule that drives naive T-cells toward the Th2 allergy-promoting fate, less IL-4, IL-5, and IL-13 production, and reduced mast cell activation.

The Evidence

The protective effect of the T allele is one of the most consistently replicated findings in asthma genetics. A study across six populations totalling over 13,000 subjects⁶⁶ A study across six populations totalling over 13,000 subjects — including children from Costa Rica, North American cohorts (CAMP), an African-American cohort (GRAAD), and the Framingham Heart Study adults — found a significant inverse association between the T allele and asthma (combined p = 2×10⁻⁵). In sex-stratified analysis, the protective effect in males was even stronger (p = 3×10⁻⁶), with odds ratios of 0.63–0.84 across cohorts.

A separate study in three independent cohorts of asthmatic children from Costa Rica, North America, and Sweden⁷⁷ from Costa Rica, North America, and Sweden found the T allele significantly reduced odds for allergen-sensitised allergic rhinitis in boys (OR 0.56–0.63; Fisher's combined p = 1.2×10⁻⁴). These effect sizes are clinically meaningful: the T allele reduces risk of allergic rhinitis complicating asthma by 37–44% in the male children studied.

The biological mechanism is directly confirmed in human tissue. Primary nasal epithelial cell experiments⁸⁸ Primary nasal epithelial cell experiments showed that the genotype effect on TSLP secretion was robust across both atopic and non-atopic individuals — meaning the T allele dampens TSLP output regardless of whether someone already has allergic disease. This is the key finding that elevates rs1837253 from a statistical association to an understood causal variant.

The sex-specific pattern — stronger in males — is intriguing and biologically plausible. Sex hormones modulate TSLP expression and the Th2/Th1 balance. In prepubertal children, boys are more commonly asthmatic than girls; after puberty the ratio reverses. The T allele may interact with androgen signalling to suppress TSLP in a male-specific fashion.

Tezepelumab (Tezspire), an anti-TSLP monoclonal antibody approved by the FDA in December 2021 for severe asthma and in 2024 for chronic rhinosinusitis with nasal polyps, directly blocks the TSLP protein. The existence of this biologic validates the TSLP pathway as the central therapeutic target in allergic airway disease. Carriers of the CC genotype — who express more TSLP — represent the population most likely to benefit from TSLP-targeting biologics.

Practical Implications

For CC carriers, understanding that elevated TSLP production underlies their allergic reactivity is clinically actionable. Strategies that reduce epithelial barrier disruption — the primary trigger for TSLP release — are specifically targeted to this mechanism. If you have severe or difficult-to-control asthma, your genotype also positions you well as a candidate for tezepelumab, which directly neutralises the TSLP protein your airways overproduce.

For CT and TT carriers, the lower TSLP baseline does not eliminate allergy risk (TSLP is not the only driver), but it does explain why some people with multiple allergy risk factors never develop clinical disease.

Interactions

TSLP does not act in isolation. Downstream of TSLP, rs2289276⁹⁹ rs2289276
A second TSLP variant showing protective association with asthma specifically in females rather than males (also in the TSLP gene) shows complementary sex-specific protection. Together, these two variants explain a substantial portion of the sex-specific inheritance of childhood asthma. The TSLP pathway also interacts with IL1RL1¹⁰¹⁰ IL1RL1
The gene encoding the IL-33 receptor, ST2 — another epithelial alarm cytokine upstream of Th2 inflammation, which has its own asthma-associated variants (rs3771180). Compound effects of TSLP and IL1RL1 risk variants on asthma risk in the Guangxi Zhuang population have been reported.